isoxazoles has been researched along with Pervasive Child Development Disorders in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boot, AM; Buitelaar, JK; Franke, B; Galesloot, TE; Roke, Y; van Harten, PN | 1 |
| Calarge, CA; Miller, del D | 1 |
| Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN | 1 |
| Buitelaar, JK; Hermans, MH; Hoekstra, PJ; Lahuis, BE; Minderaa, RB; Scahill, L; Troost, PW; van Engeland, H | 1 |
| Jones, BD; Labelle, A; Lit, W; Purdon, SE | 1 |
1 trial(s) available for isoxazoles and Pervasive Child Development Disorders
| Article | Year |
|---|---|
Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Child, Preschool; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Prolactin; Prospective Studies; Pyrimidines; Risperidone | 2007 |
4 other study(ies) available for isoxazoles and Pervasive Child Development Disorders
| Article | Year |
|---|---|
The effect of the Taq1A variant in the dopamine Dâ‚‚ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Topics: Adolescent; Alleles; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child Development Disorders, Pervasive; Cytochrome P-450 CYP2D6; Drug Administration Schedule; Genetic Variation; Humans; Hyperprolactinemia; Isoxazoles; Male; Paliperidone Palmitate; Polymorphism, Genetic; Prolactin; Pyrimidines; Receptors, Dopamine D2; Risperidone; Young Adult | 2013 |
Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Topics: Adolescent; Aging; Antipsychotic Agents; Body Mass Index; Child; Child Development Disorders, Pervasive; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Therapy, Combination; Female; Humans; Isoxazoles; Male; Mental Disorders; Paliperidone Palmitate; Polypharmacy; Psychotic Disorders; Pyrimidines; Risperidone; Sex Factors; Sexual Development | 2011 |
Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child Development Disorders, Pervasive; Cross-Sectional Studies; Dose-Response Relationship, Drug; Gynecomastia; Humans; Hyperprolactinemia; Isoxazoles; Logistic Models; Male; Paliperidone Palmitate; Prolactin; Pyrimidines; Risperidone; Sexual Dysfunction, Physiological; Statistics, Nonparametric; Surveys and Questionnaires; Time Factors; Young Adult | 2012 |
Risperidone in the treatment of pervasive developmental disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Follow-Up Studies; Humans; Intellectual Disability; Isoxazoles; Male; Neuropsychological Tests; Piperidines; Risperidone; Serotonin; Stereotyped Behavior | 1994 |